Definium's LSD-based pill meets Phase 3 goals in anxiety disorder trial
Tweet Send to a Friend
Definium Therapeutics (Nasdaq: DFTX) announced that its Phase 3 Voyage study of DT120 (lysergide) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
